Showing results (671-680 of 682) with videos related to

Sort By:
Pageof 69
Blood|April 14, 2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaPaul G Richardson, Edie Weller, Sagar Lonial, et al.
Nature Genetics|January 19, 2010
AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisisCarrie M Louie, Gianluca Caridi, Vanda S Lopes, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2024
Lanthanide binding peptide surfactants at air-aqueous interfaces for interfacial separation of rare earth elementsLuis E Ortuno Macias, Felipe Jiménez-Ángeles, Jason G Marmorstein, et al.
Nature Genetics|January 17, 2012
CEP41 is mutated in Joubert syndrome and is required for tubulin glutamylation at the ciliumJi Eun Lee, Jennifer L Silhavy, Maha S Zaki, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
The Lancet. Haematology|August 23, 2017
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trialSarah A Holstein, Sin-Ho Jung, Paul G Richardson, et al.
Nature Communications|June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantTarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
The New England Journal of Medicine|May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myelomaPhilip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
Cell Reports|January 6, 2021
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of OncoproteinsRyosuke Shirasaki, Geoffrey M Matthews, Sara Gandolfi, et al.
The Lancet. Oncology|September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialJesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
Pageof 69